Patent SG-11201407190T-A (SG)
Title: Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
Inventor: COGSWELL JOHN P
IPC: C07K16/28
Filed: 2013-05-13
Abstract: (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 21 November 2013 (21.11.2013) WIPOIPCT (10) International Publication Number WO 2013/173223 A1 (51) International Patent Classification: C07K16/28 (2006.01) (21) International Application Number: PCT/US2013/040764 (22) International Filing Date: 13 May 2013 (13.05.2013) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 61/647,442 15 May 2012 (15.05.2012) US 61/790,747 15 March 2013 (15.03.2013) US (71) Applicant: BRISTOL-MYERS SQUIBB COMPANY [US/US]; Route 206 and Province Line Road, Princeton, New Jersey 08543-4000 (US). (72) Inventors: COGSWELL, John P.; c/o Bristol-Myers Squibb Company, Route 206 and Province Line Road, Princeton, New Jersey 08543 (US). GOLDBERG, Stacie M.; c/o Bristol-Myers Squibb Company, Route 206 and Province Line Road, Princeton, New Jersey 08543 (US). GUPTA, Ashok K.; c/o Bristol-Myers Squibb Company, Route 206 and Province Line Road, Princeton, New Jersey 08543 (US). JURE-KUNKEL, Maria; c/o Bristol-Myers Squibb Company, Route 206 and Province Line Road, Princeton, New Jersey 08543 (US). WANG, Xi Tao; c/o Bristol-Myers Squibb Company, Route 206 and Province Line Road, Princeton, New Jersey 08543 (US). WIGGIN- TON, Jon M.; c/o Bristol-Myers Squibb Company, Route 206 and Province Line Road, Princeton, New Jersey 08543 (US). (74) Agents: DELAUNEY, Ashton J. et al.; Bristol-Myers Squibb Company, P.O. Box 4000, Princeton, New Jersey 08543-4000 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available)'. AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available)'. ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: — of inventorship (Rule 4.17(iv)) [Continued on next page] (54) Title: CANCER IMMUNOTHERAPY BY DISRUPTING PD-l/PD-Ll SIGNALING Pretreatment 2 months 4 months m CJ CJ m i> i-H cn i-H o CJ O £ FIG. 7 (57) Abstract: The disclosure provides method for a immunotherapy of a cancer patient, comprises administering to the patient an Ab that inhibits signaling from the PD-l/PD-Ll signaling pathway, or a combination of such Ab and an anti-CTLA-4 Ab. This dis - closure also provides a method for immunotherapy of cancer patient comprising a selecting a patient who is a suitable candidate for immunotherapy based on an assessment that the proportion of cells in a test tissue sample from the patient that express PD-L1 on the cell surface exceeds a predetermined threshold level, and administering an anti-PD-1 Ab to the selected subject. The disclosure addi - tionally provides rabbit mAbs that bind specifically to a cell surface-expressed PD-L1 antigen in FFPE a tissue sample, and an auto - mated IHC method for assessing cell surface expression in FFPE tissues using the provided anti-PD-Ll Abs. WO 2013/173223 A11 lllll llllllll II llllll III lllll lllll lllll III III III lllll lllll lllll lllll llll lllllll llll llll llll Published: — with international search report (Art. 21(3)) — before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) — with sequence listing part of description (Rule 5.2(a))